A biopsychosocial model of interferon-alpha-induced depression in patients with chronic hepatitis C infection

Psychotherapy and Psychosomatics

Volumn 82, Issue 5, 2013, Pages 332-340

  Baranyi, Andreas ^a   Meinitzer, Andreas ^b   Stepan, Alexandra ^a   Putz Bankuti, Csilla ^a   Breitenecker, Robert J ^c   Stauber, Rudolf ^a   Kapfhammer, Hans Peter ^a   Rothenhäusler, Hans Bernd ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b Clinical Institute of Medical and Chemical Laboratory Diagnostics   (Austria)

^c UNIVERSITY OF KLAGENFURT   (Austria)

Author keywords

Cognition; Depression; Health related quality of life; Hepatitis C; Interferon; Life satisfaction; Neurotoxic challenge; Social support; Tryptophan depletion

Indexed keywords

ALPHA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENIC ACID; KYNURENINE; TRYPTOPHAN;

ADULT; ARTICLE; BECK DEPRESSION INVENTORY; CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG INDUCED DISEASE; FEMALE; HAMILTON SCALE; HEPATITIS C; HUMAN; LIFE SATISFACTION; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOMETRY; QUALITY OF LIFE; SOCIAL ENVIRONMENT; SOCIAL SUPPORT; CHRONIC HEPATITIS C; DEPLETION; EMOTIONAL DISORDER; HEALTH; MENTAL HEALTH; PAIN; RISK FACTOR; SEXUAL SATISFACTION; SOCIAL INTERACTION;

ADULT; ANALYSIS OF VARIANCE; DEPRESSIVE DISORDER; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON-ALPHA; INTERVIEW, PSYCHOLOGICAL; KYNURENIC ACID; KYNURENINE; MALE; MODELS, THEORETICAL; NEUROPSYCHOLOGICAL TESTS; PERSONAL SATISFACTION; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; QUESTIONNAIRES; RISK FACTORS; SEX FACTORS; SOCIAL SUPPORT; THYROID FUNCTION TESTS; TRYPTOPHAN;

EID: 84883156139     PISSN: 00333190     EISSN: 14230348     Source Type: Journal    
DOI: 10.1159/000348587     Document Type: Article

References (38)

1. Crone C, Gabriel GM: Comprehensive review of hepatitis C for psychiatrists: risks, screening, diagnosis, treatment, and interferonbased therapy complications. J Psychiatr Pract 2003; 9: 93-110.
2. Dinwiddie SH, Shicker L, Newman T: Prevalence of hepatitis C among psychiatric patients in the public sector. Am J Psychiatry 2003; 160: 172-174.
3. Udina M, Castellvi P, Moreno-Espana J, Navines R, Valdes M, Forns X, Langohr K, Sola R, Vieta E, Martin-Santos R: Interferoninduced depression in chronic hepatitis C: a systematic review and meta-analysis. J Clin Psychiatry 2012; 73: 1128-1138.
4. Grassi L, Satriano J, Serra A, Biancosino B, Zotos S, Sighinolfi L, Ghinelli F: Emotional stress, psychosocial variables and coping associated with hepatitis C virus and human immunodeficiency virus infections in intravenous drug users. Psychother Psychosom 2002; 71: 342-349.
5. Patten SB, Barbui C: Drug-induced depression: a systematic review to inform clinical practice. Psychother Psychosom 2004; 73: 207-215.
6. Bonaccorso S, Marino V, Biondi M, Grimaldi F, Ippoliti F, Maes M: Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. J Affect Disord 2002; 72: 237-241.
7. Bonaccorso S, Marino V, Puzella A, Pasquini M, Biondi M, Artini M, Almerighi C, Verkerk R, Meltzer H, Maes M: Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol 2002; 22: 86-90.
8. Raison CL, Borisov AS, Broadwell SD, Capuron L, Woolwine BJ, Jacobson IM, Nemeroff CB, Miller AH: Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry 2005; 66: 41-48.
9. Wichers MC, Koek GH, Robaeys G, Verkerk R, Scharpe S, Maes M: IDO and interferonalpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry 2005; 10: 538-544.
10. Wichers M, Maes M: The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. Int J Neuropsychopharmacol 2002; 5: 375-388.
11. McHutchison JG, Ware JE Jr, Bayliss MS, Pianko S, Albrecht JK, Cort S, Yang I, Neary MP, Hepatitis Interventional Therapy Group: The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol 2001; 34: 140-147.
12. Fava GA, Freyberger HJ, Bech P, Christodoulou G, Sensky T, Theorell T, Wise TN: Diagnostic criteria for use in psychosomatic research. Psychother Psychosom 1995; 63: 1-8.
13. Fava GA, Mangelli L, Ruini C: Assessment of psychological distress in the setting of medical disease. Psychother Psychosom 2001; 70: 171-175.
14. Fava GA, Ruini C, Tomba E, Wise TN: The biopsychosocial factor. Psychother Psychosom 2012; 81: 1-4.
15. Tomba E, Bech P: Clinimetrics and clinical psychometrics: macro-and micro-analysis. Psychother Psychosom 2012; 81: 333-343.
16. Herve C, Beyne P, Jamault H, Delacoux E: Determination of tryptophan and its kynurenine pathway metabolites in human serum by high-performance liquid chromatography with simultaneous ultraviolet and fluorimetric detection. J Chromatogr B Biomed Appl 1996; 675: 157-161.
17. Schwarz EL, Roberts WL, Pasquali M: Analysis of plasma amino acids by HPLC with photodiode array and fluorescence detection. Clin Chim Acta 2005; 354: 83-90.
18. Lehfeld H, Erzigkeit H: The SKT-a short cognitive performance test for assessing deficits of memory and attention. Int Psychogeriatr 1997; 9(suppl 1):115-121.
19. Ware JE, Snow KK, Kosinski M, Gandek B: SF-36 Health Survey. Manual and Interpretation Guide. Boston, Health Institute, New England Medical Center, 2008.
20. Stewart AL, Hays RD, Ware JE: The MOS short-form general health survey. Reliability and validity in a patient population. Med Care 1988; 26: 724-735.
21. Fahrenberg J, Myrtek M, Schuhmacher J: Fragebogen zur Lebenszufriedenheit (FLZ) Handanweisung. Gottingen, Hogrefe, 2000.
22. Sherbourne CD, Stewart AL: The MOS social support survey. Soc Sci Med 1991; 32: 705-714.
23. Hamilton M: Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6: 278-296.
24. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J: An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561-571.
25. Stein MD, Solomon DA, Herman DS, Anderson BJ, Miller I: Depression severity and drug injection HIV risk behaviors. Am J Psychiatry 2003; 160: 1659-1662.
26. Malaguarnera M, Laurino A, Di Fazio I, Pistone G, Castorina M, Guccione N, Rampello L: Neuropsychiatric effects and type of IFNalpha in chronic hepatitis C. J Interferon Cytokine Res 2001; 21: 273-278.
27. Dieperink E, Willenbring M, Ho SB: Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am J Psychiatry 2000; 157: 867-876.
28. O'Connor JC, Lawson MA, Andre C, Briley EM, Szegedi SS, Lestage J, Castanon N, Herkenham M, Dantzer R, Kelley KW: Induction of IDO by bacille Calmette-Guerin is responsible for development of murine depressive-like behavior. J Immunol 2009; 182: 3202-3212.
29. Schaefer M, Winterer J, Sarkar R, Uebelhack R, Franke L, Heinz A, Friebe A: Three cases of successful tryptophan add-on or monotherapy of hepatitis C and IFN-alpha-associated mood disorders. Psychosomatics 2008; 49: 442-446.
30. Raison CL, Dantzer R, Kelley KW, Lawson MA, Woolwine BJ, Vogt G, Spivey JR, Saito K, Miller AH: CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol Psychiatry 2010; 15: 393-403.
31. Wilson MP, Castillo EM, Batey AM, Sapyta J, Aronson S: Hepatitis C and depressive symptoms: psychological and social factors matter more than liver injury. Int J Psychiatry Med 2010; 40: 199-215.
32. Marcellin P, Lau GK, Zeuzem S, Heathcote EJ, Pockros PJ, Reddy KR, Piratvisuth T, Farci P, Chow WC, Jia JD, Paik W, Wintfeld N, Pluck N: Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a. Liver Int 2008; 28: 477-485.
33. Dan AA, Martin LM, Crone C, Ong JP, Farmer DW, Wise T, Robbins SC, Younossi ZM: Depression, anemia and health-related quality of life in chronic hepatitis C. J Hepatol 2006; 44: 491-498.
34. McAndrews MP, Farcnik K, Carlen P, Damyanovich A, Mrkonjic M, Jones S, Heathcote EJ: Prevalence and significance of neurocognitive dysfunction in hepatitis C in the absence of correlated risk factors. Hepatology 2005; 41: 801-808.
35. Reichenberg A, Gorman JM, Dieterich DT: Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a week prospective study. AIDS 2005; 19(suppl 3):S174-S178.
36. Wobrock T, Mihm U, Lohr C, Hofmann WP, Sarrazin C, Zeuzem S, Falkai P: Cognition in hepatitis C patients treated with pegylated interferon. World J Biol Psychiatry 2009; 10: 819-826.
37. Evon DM, Ramcharran D, Belle SH, Terrault NA, Fontana RJ, Fried MW, Virahep-C Study Group: Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the Virahep-C study. Am J Gastroenterol 2009; 104: 2949-2958.
38. Capuron L, Ravaud A, Miller AH, Dantzer R: Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferonalpha cancer therapy. Brain Behav Immunol 2004; 18: 205-213.